Romiplostim for the treatment of chronic immune thrombocytopenia

Technology appraisal guidance
Reference number: TA221
Published: 27 April 2011
Last updated: 26 October 2018

Thrombocytopenic purpura - romiplostim: consultee and commentator comments on the ACD

Thrombocytopenic purpura - romiplostim: consultee and commentator comments on the ACD received from Amgen
Thrombocytopenic purpura - romiplostim: consultee and commentator comments on the ACD received from the ITP Support Association
Thrombocytopenic purpura - romiplostim: consultee and commentator comments on the ACD received from the Royal College of Nursing
Thrombocytopenic purpura - romiplostim: consultee and commentator comments on the ACD received from the Royal College of Pathologists and British Society for Haematology
Thrombocytopenic purpura - romiplostim: consultee and commentator comments on the ACD received from the Department of Health
Thrombocytopenic purpura - romiplostim: consultee and commentator comments on the ACD received from GlasxoSmithKline
Thrombocytopenic purpura - romiplostim: consultee and commentator comments on the ACD received via the NICE website

This page was last updated: 15 March 2011